High-Grade Glioma Market Is Predicted to Exhibit Remarkable Growth by 2032 – DelveInsight | Key Companies – BioMimetix, Oncoceutics, Istari, Aadi Bioscience, Bristol-Myers Squibb, and Others

Delveinsight Business Research LLP
DelveInsight’s “High-Grade Glioma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the High-Grade Glioma Market Size and Share in the 7MM (i.e. the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The High-Grade Glioma market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

High-Grade Glioma: An Overview

Highly Malignant or High-Grade Gliomas (HGG) are tumors of the central nervous system (CNS). They are solid tumors arising from transformed cells called astrocytes of the brain and/or the spinal cord. Since they directly originate from the CNS, they are also called primary CNS tumors, thereby differentiating them from malignant tumors of other organs that have spread (metastasized) to the CNS.

Various types of HGG have been identified based on their localization within the central nervous system (CNS), the cell of origin, and the degree of malignancy, such as diffuse intrinsic pontine gliomas, anaplastic astrocytomas (WHO-grade III), and glioblastoma multiforme (WHO-grade IV).

High-Grade Glioma Market Key Facts

According to The Royal Marsden, NHS Foundation Trust, HGG are the most common type of adult brain tumor and although they look the same under the microscope, they may be different biologically. Less than 30 children a year develop high-grade glioma in the UK. This is about 8% of all childhood brain and spinal cord tumors.

Diffuse midline glioma, H3 K27M-mutant (formerly called diffuse intrinsic pontine glioma (DIPG) is a high-grade tumor that is found in the brainstem. These tumors account for 10% of all brain tumors in children. Additionally, as per Ebrahimi et al., H3 K27M mutations in adult midline tumors are frequent (24% of all adult cases fulfilled the criteria for a diffuse midline glioma, H3 K27M mutant). 

High-Grade Glioma Treatment

HGG is a very difficult tumor to treat due to the problems in completely removing the tumor and their resistance to radiotherapy and chemotherapy.  The most effective treatment for HGG patients is a combination of neurosurgery, radiotherapy, and chemotherapy. Among these treatment modalities, neurosurgery is of the highest impact, since the extent of tumor removal significantly determines the further course of the disease.

More recently, advances have been made in the field of chimeric antigen receptor (CAR) T cells as a targeted therapy targeting anti-GD2 for HGG. However, these studies remain in the early stages. With these limited treatment options, there remains a critical need to develop novel therapeutics and effective delivery mechanisms for HGG.

High-Grade Glioma Market

The High-Grade Glioma (HGG) Market Size is expected to increase during the forecast period owing to the launch of the emerging therapies.

The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted High-Grade Glioma market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives a thorough detail of the High-Grade Glioma market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.

High-Grade Glioma Epidemiology

The epidemiology section covers insights about the historical and current High-Grade Glioma patient pool and forecasted trends for every seven major countries (7MM)  from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

High-Grade Glioma Epidemiology Segmentation –

Incident Population of High-Grade Glioma (HGG)

Incident Population of CNS Brain Tumour

Gender-specific Incidence of High-Grade Glioma (HGG)

Type-specific Incidence of High-Grade Glioma (HGG)

Mutation-specific Incidence (specifically H3K27M mutation)

Diagnosed and Treatable Cases of High-Grade Glioma

High-Grade Glioma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the High-Grade Glioma market or expected to get launched in the market during the study period. The analysis covers High-Grade Glioma market uptake by drugs; patient uptake by therapies; and sales of each drug. 

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The report also covers the High-Grade Glioma Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.

Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/high-grade-glioma-market

High-Grade Glioma Therapeutics Analysis

The dynamics of the High-grade Glioma market is anticipated to change in the coming years owing to the positive outcomes of the emerging pipeline candidates during the developmental stage by key players. The launch of emerging therapies is expected during the forecast period.

High-Grade Glioma Companies:

BioMimetix 

Oncoceutics 

Istari Oncology 

Aadi Bioscience 

Bristol-Myers Squibb 

Sumitomo Dainippon Pharma 

And Many Others

High-Grade Glioma Therapies covered in the report include:

BMX-001

ONC201

Opdivo

ABI-009

PVSRIPO

DSP-7888

And many more.

Get More Detailed Insights into the Emerging Therapies & Key Companies:-  https://www.delveinsight.com/sample-request/high-grade-glioma-market

Table of Content

1. Key Insights

2. Executive Summary 

3. High-Grade Glioma Competitive Intelligence Analysis

4. High-Grade Glioma Market Overview at a Glance

5. High-Grade Glioma Disease Background and Overview

6. High-Grade Glioma Patient Journey

7. High-Grade Glioma Epidemiology and Patient Population

8. High-Grade Glioma Treatment Algorithm, Current Treatment, and Medical Practices

9. High-Grade Glioma Unmet Needs

10. Key Endpoints of High-Grade Glioma Treatment

11. High-Grade Glioma Marketed Products

12. High-Grade Glioma Emerging Therapies

13. High-Grade Glioma Seven Major Market Analysis

14. Attribute Analysis

15. High-Grade Glioma Market Outlook (7 major markets)

16. High-Grade Glioma Access and Reimbursement Overview

17. KOL Views on the High-Grade Glioma Market.

18. High-Grade Glioma Market Drivers

19. High-Grade Glioma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The table of contents is not exhaustive; the final content may vary. 

Request Sample Report here:-  https://www.delveinsight.com/sample-request/high-grade-glioma-market

Other Latest Healthcare Reports By DelveInsight

Bevacizumab Biosimilars Insight

DelveInsight’s, “Bevacizumab Biosimilar Insight” report provides comprehensive insights about 40+ companies and 40+ marketed and pipeline drugs in the Bevacizumab Biosimilars landscape. The report also covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products.

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/